The MISTRAL-C trial showed that using the Sentinel CPS in TAVR procedures captures brain-bound cerebral debris, leading to fewer and smaller new brain lesions, minimizing the risk of neurocognitive deterioration.
Investigators in the Valve-in-Valve (VinV) study concluded that the Sentinel CPS can protect the brain from embolic debris and that in their early case series there were no patients who had a stroke when protection was used.
ARIC cohort study shows even very small brain lesions may increase risk of future stroke and death >3-fold.3
Cerebral protection in TAVI. (2016, February 11). JIM Today, Issue 1.
O’Riordan, M. ‘’Encouraging” Early Findings with Embolic Protection in TEVAR, Suggests Small Pilot Study, tctmd.com, 9 Feb. 2016.
An educational webinar for physicians presented by New York-Presbyterian/Columbia University Medical Center
Embolic Protection in TAVR: Is it Necessary?
Moderator: Susheel K. Kodali, M.D.
Faculty: Ron Lazar, M.D., Tamim Nazif, M.D.
- “Major stroke is not the only thing we worry about…cognitive decline is equally as important.”
- “I find the (Clean-TAVI) data provocative and very exciting, particularly the (brain) MRI data looking at the number and volume of lesions.”
- “Any reduction in reserve (brain capacity) is not a positive thing.”
Watch an interview from EUROPCR 2015
Cerebral Protection in TAVI: Theory and Practice From EuroPCR 2015
With Nicolas Van Mieghem, MD. Thoraxcenter, Erasmus Medical Center, Rotterdam
- “Why would we not want to protect the brain in our patients?”
- “2/3 of all TAVI patients (in my study) have some kind of tissue debris (captured) in the (Claret) filters”
- “(Small brain) infarcts are linked to premature dementia and neurocognitive deficits.”
- “85% of our (TAVI) cases are being done with (Claret) filters. It takes me less than 2 minutes to introduce (them).”
The Sentinel CPS has received the CE Mark and is commercially available in Europe. It is limited to investigational use in the United States.